OXFORD, England, October 30, 2025--(BUSINESS WIRE)--ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE ® SL Self-Loading MHC Class I ...
Immune checkpoint therapies (ICT) for advanced solid tumors mark a new milestone in cancer therapy. Yet their efficacy is often limited by poor immunogenicity, attributed to inadequate priming and ...
In this schematic of peptide loading on class-I MHC proteins, the molecular chaperone TAPBPR (blue) catalyzes the loading of a small peptide antigen (purple), derived from a viral or tumor protein, on ...
Tapasin enhances the loading and editing of peptide 'cargo' onto major histocompatibility complex class I molecules, yet it cannot do so alone. Two new reports show that the oxidoreductase ERp57 ...
ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE SL Self-Loading MHC Class I Monomers. The novel reagents for antigen-specific CD8+ T ...
ProImmune launches ProVE SL self-loading MHC Class I monomers to improve T cell research flexibility
ProImmune Ltd, a global leader in life science reagents and services, announced the launch of its new ProVE SL self-loading MHC Class I monomers. The novel reagents for antigen-specific CD8+ T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results